SI3442578T1 - Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka - Google Patents

Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka

Info

Publication number
SI3442578T1
SI3442578T1 SI201731120T SI201731120T SI3442578T1 SI 3442578 T1 SI3442578 T1 SI 3442578T1 SI 201731120 T SI201731120 T SI 201731120T SI 201731120 T SI201731120 T SI 201731120T SI 3442578 T1 SI3442578 T1 SI 3442578T1
Authority
SI
Slovenia
Prior art keywords
cancer
agents
determining
treatment
methods
Prior art date
Application number
SI201731120T
Other languages
English (en)
Inventor
Irving L. Weissman
Mark P. Chao
Ravindra Majeti
Jie Liu
Jens-Peter Volkmer
Original Assignee
The Board Of Trustees Of The Leland Standford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Standford Junior University filed Critical The Board Of Trustees Of The Leland Standford Junior University
Publication of SI3442578T1 publication Critical patent/SI3442578T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201731120T 2016-04-15 2017-04-14 Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka SI3442578T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662323330P 2016-04-15 2016-04-15
US201662427679P 2016-11-29 2016-11-29
EP17783254.0A EP3442578B1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer
PCT/US2017/027662 WO2017181033A1 (en) 2016-04-15 2017-04-14 Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer

Publications (1)

Publication Number Publication Date
SI3442578T1 true SI3442578T1 (sl) 2022-05-31

Family

ID=60042716

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201731120T SI3442578T1 (sl) 2016-04-15 2017-04-14 Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka

Country Status (12)

Country Link
US (3) US11472878B2 (sl)
EP (3) EP4349412A2 (sl)
JP (3) JP2019515899A (sl)
KR (3) KR102505253B1 (sl)
CN (3) CN117695387A (sl)
AU (1) AU2017250809B2 (sl)
CA (1) CA3019676A1 (sl)
ES (1) ES2909835T3 (sl)
PL (1) PL3442578T3 (sl)
PT (1) PT3442578T (sl)
SI (1) SI3442578T1 (sl)
WO (1) WO2017181033A1 (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018081898A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Improvements in cd47 blockade therapy by hdac inhibitors
AU2018351006A1 (en) 2017-10-18 2020-05-07 Forty Seven, Inc. Anti-CD47 agent-based ovarian cancer therapy
ES2927305T3 (es) 2018-02-12 2022-11-04 Forty Seven Inc Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20
JP2021529219A (ja) * 2018-07-05 2021-10-28 トリカン・バイオテクノロジー・カンパニー・リミテッドTrican Biotechnology Co., Ltd ヒト抗cd47抗体およびその使用
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
WO2020112687A2 (en) 2018-11-26 2020-06-04 Forty Seven, Inc. Humanized antibodies against c-kit
KR20210094609A (ko) 2018-11-28 2021-07-29 포티 세븐, 인코포레이티드 절제 레짐에 대해 저항성인 유전적으로 변형된 hspc
KR20220113353A (ko) 2019-09-18 2022-08-12 람캅 바이오 알파 에이지 Ceacam5 및 cd3에 대한 이중특이적 항체
CA3164623A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
PE20230116A1 (es) * 2020-04-06 2023-01-27 Univ Leland Stanford Junior Formulacion de anticuerpos
WO2023002415A2 (en) * 2021-07-20 2023-01-26 Magenta Therapeutics, Inc. Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3054220C (en) 2008-01-15 2022-10-11 The Board Of Trustees Of The Leland Stanford Junior University Methods for manilpulating phagocytosis mediated by cd47
LT3789038T (lt) 2010-05-14 2022-12-12 The Board Of Trustees Of The Leland Stanford Junior University Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47
CN104136037B (zh) 2012-01-17 2018-02-23 小利兰·斯坦福大学托管委员会 高亲和力SIRP‑α试剂
BR112014019331A2 (pt) 2012-02-06 2022-07-12 Inhibrx Inc anticorpos para cd47 e métodos de uso desses
SG10201706383XA (en) * 2013-02-06 2017-09-28 Inhibrx Lp Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
ES2728066T3 (es) * 2013-03-15 2019-10-22 Univ Leland Stanford Junior Métodos para la obtención de dosis terapéuticamente eficaces de agentes anti-CD47
KR102175688B1 (ko) 2013-03-27 2020-11-06 제넨테크, 인크. 베타7 인테그린 길항제를 사용하는 위장 염증성 장애의 치료를 평가하기 위한 바이오마커의 사용
CA2910466A1 (en) 2013-04-29 2014-11-06 The Board Of Trustees Of The Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
EP3052119B1 (en) 2013-10-01 2018-08-22 The U.S.A. as represented by the Secretary, Department of Health and Human Services Methods of modulating erythropoiesis with arginine vasopressin receptor 1b molecules
AU2015204766B2 (en) * 2014-01-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2016028810A1 (en) 2014-08-18 2016-02-25 Biogen Ma Inc. Anti-cd40 antibodies and uses thereof

Also Published As

Publication number Publication date
EP3442578A4 (en) 2019-04-10
US11472878B2 (en) 2022-10-18
CN115350276A (zh) 2022-11-18
AU2017250809A1 (en) 2018-10-25
JP7442591B2 (ja) 2024-03-04
KR20240016445A (ko) 2024-02-06
US11718670B2 (en) 2023-08-08
AU2017250809B2 (en) 2024-02-29
CN109152837A (zh) 2019-01-04
JP2019515899A (ja) 2019-06-13
PL3442578T3 (pl) 2022-06-20
ES2909835T3 (es) 2022-05-10
EP4349412A2 (en) 2024-04-10
PT3442578T (pt) 2022-05-19
EP4074339A1 (en) 2022-10-19
US20230406923A1 (en) 2023-12-21
CA3019676A1 (en) 2017-10-19
US20230068235A1 (en) 2023-03-02
EP3442578B1 (en) 2022-02-09
WO2017181033A1 (en) 2017-10-19
JP2022172278A (ja) 2022-11-15
KR20230035435A (ko) 2023-03-13
EP3442578A1 (en) 2019-02-20
KR20180134367A (ko) 2018-12-18
JP2024059764A (ja) 2024-05-01
US20190106491A1 (en) 2019-04-11
KR102505253B1 (ko) 2023-03-02
CN117695387A (zh) 2024-03-15

Similar Documents

Publication Publication Date Title
SI3442578T1 (sl) Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka
ZA201904695B (en) Amino-triazolopyridine compounds and their use in treating cancer
HK1257249A1 (zh) 使用脂質體伊立替康和parp抑制劑用於癌症治療的組合療法
ZA201701491B (en) Methods and therapeutic combinations for treating tumors
IL266198A (en) Liposomal formulation for use in cancer treatment
IL254842A0 (en) Therapeutic preparations and methods for use in cancer treatment
IL266182A (en) Farensyltransferase inhibitors for use in cancer treatment methods
HK1245096A1 (zh) 用於癌症治療的細胞治療劑以及使用該細胞治療劑的聯合治療
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
SG10202001388YA (en) Use of ureidomustine (bo-1055) in cancer treatment
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
PL3325478T3 (pl) Nowy związek terapeutyczny i zastosowanie w terapii
GB201600637D0 (en) Therapeutic treatment methods and apparatus for use therein
GB201612793D0 (en) Therapeutic use of quesnoin in colorectal cancer treatment
GB201612794D0 (en) Therapeutic use of diethanololeamide in prostate cancer treatment
AU2016905362A0 (en) Compounds and use thereof in methods of treatment
GB201510764D0 (en) bis-Pyridazine compounds and their use in treating cancer
GB201418640D0 (en) Agents and methods for treatment of cancer